Cargando…

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia

Mostrar otras versiones (1)

BACKGROUND: As there are limited patients for chronic lymphocytic leukaemia trials, it is important that statistical methodologies in Phase II efficiently select regimens for subsequent evaluation in larger-scale Phase III trials. METHODS: We propose the screened selection design (SSD), which is a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Christina, Pettitt, Andrew, Billingham, Lucinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726070/ https://www.ncbi.nlm.nih.gov/pubmed/23819695 http://dx.doi.org/10.1186/1471-2288-13-87

Ejemplares similares

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
por: Yap, Christina, et al.
Publicado: (2011)

Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges
por: Yap, Christina, et al.
Publicado: (2013)

Dose transition pathways: a design, analysis and operational tool for dose-finding trials using model-based designs
por: Yap, Christina, et al.
Publicado: (2015)

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials – an example in hemato-oncology
por: Jacob, Louis, et al.
Publicado: (2016)

Implementing the EffTox dose-finding design in the Matchpoint trial
por: Brock, Kristian, et al.
Publicado: (2017)

Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design
por: Khan, Josephine, et al.
Publicado: (2013)

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions
por: Burke, Danielle L, et al.
Publicado: (2014)

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing’s sarcoma
por: Dutton, P, et al.
Publicado: (2016)

Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis
por: Zhuang, Jianguo, et al.
Publicado: (2014)

Modelling clinical trial recruitment using poisson processes
por: Brock, Kristian, et al.
Publicado: (2015)

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
por: Pascoe, Jennifer, et al.
Publicado: (2021)

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
por: Dillon, Richard, et al.
Publicado: (2022)

Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials
por: Mossop, Helen, et al.
Publicado: (2021)

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
por: Menne, Tobias, et al.
Publicado: (2022)

Comparison of a frequentist and Bayesian response-adaptive randomisation approach in multi-stage phase II selection trials with multiple experimental arms
por: Yap, Christina, et al.
Publicado: (2015)

Looking ahead in early-phase trial design to improve the drug development process: examples in oncology
por: Vanderbeek, Alyssa M., et al.
Publicado: (2023)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

Health technology assessment: oncology drugs with orphan designation as an example
por: Wild, Claudia
Publicado: (2010)

A Case of Lymphocytic Leukæmia
por: Reynolds, Fredrick H.
Publicado: (1933)

Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia
por: Mentese, Ahmet, et al.
Publicado: (2018)

Alemtuzumab in T-cell large granular lymphocytic leukaemia: a phase 2 study
por: Dumitriu, Bogdan, et al.
Publicado: (2015)

Design, power, and alpha levels in randomized phase II oncology trials
por: Haslam, A., et al.
Publicado: (2023)

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak
por: Melarangi, T, et al.
Publicado: (2012)

Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells
por: Eagle, Gina L., et al.
Publicado: (2021)

Seasonality in the diagnosis of acute lymphocytic leukaemia.
por: Badrinath, P., et al.
Publicado: (1997)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions
por: Pantel, Austin R., et al.
Publicado: (2022)

Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
por: Guo, Beibei, et al.
Publicado: (2014)

A case of leukaemia cutis in a dog with T‐cell chronic lymphocytic leukaemia
por: Bae, Hyeona, et al.
Publicado: (2022)

Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases
por: Billingham, Lucinda, et al.
Publicado: (2013)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
por: Parker, H, et al.
Publicado: (2016)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects
por: Alharthi, Afaf, et al.
Publicado: (2018)

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
por: Till, Kathleen J., et al.
Publicado: (2017)

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
por: Ferry, David, et al.
Publicado: (2017)

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
por: Cull, Gavin, et al.
Publicado: (2021)

Crossing survival curves: alternatives to the log-rank test
por: Bouliotis, George, et al.
Publicado: (2011)

Ribosomal RNA Synthesis in Chronic Lymphocytic Leukaemia
por: Billington, R. W., et al.
Publicado: (1974)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_avc2bss88v856q7uob0b2kk0ae